Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Orthopaedics, The First Hospital of China Medical University, Shenyang, China.
Ann Palliat Med. 2021 Aug;10(8):9057-9068. doi: 10.21037/apm-21-1836. Epub 2021 Aug 12.
Idiopathic pulmonary fibrosis (IPF) is a life-threatening disease, the progression of which current drug therapy cannot reverse. This study analyzed current research hotspots and future research trends in IPF through bibliometric methods, with the aim of providing a reference for new therapeutic strategies.
Publications on IPF obtained from the Web of Science Core Collection database, The Literature Metrology Online Analysis Platform, and CiteSpace were used to analyze publication characteristics. VOSviewer was used to conduct keywords co-occurrence analysis and analyze research hotspots.
A total of 7,016 publications related to IPF were identified from 2011 to 2020. The most contributions were from the USA and the five research institutions with the largest number of publications were all from that country. The American Journal of Respiratory and Critical Care Medicine was the most cited journal and had an incontrovertible academic impact with five of the top 10 high-cited references published in this journal. G Raghu was the academic authority in this domain in terms of both the number of publications and the most citations. By analyzing keywords, we identified three IPF research hotspot clusters, which are "clinical research", "pathogenesis research" and "diagnosis research" respectively.
We evaluated all publications concerning IPF research in the past decade through bibliometric analysis. The current research hotspot in this field is drug therapy for the condition using nintedanib and pirfenidone. Future research will focus on conducting multi-center randomized controlled trials to explore and evaluate new therapeutic drugs for IPF. It is hoped that this study can provide information and data support for further research and the development of new therapeutic drugs.
特发性肺纤维化(IPF)是一种危及生命的疾病,目前的药物治疗无法逆转其进展。本研究通过文献计量学方法分析了 IPF 的当前研究热点和未来研究趋势,旨在为新的治疗策略提供参考。
从 Web of Science 核心合集数据库、文献计量在线分析平台和 CiteSpace 中获取有关 IPF 的出版物,以分析出版物特征。使用 VOSviewer 进行关键词共现分析,并分析研究热点。
2011 年至 2020 年共确定了 7016 篇与 IPF 相关的出版物。贡献最多的是美国,发表论文数量最多的五家研究机构均来自该国。《美国呼吸与危重症医学杂志》是被引频次最高的期刊,其中有五篇位列被引频次最高的前 10 位的参考文献出自该期刊,具有不可争议的学术影响力。在发表论文数量和被引频次方面,G Raghu 都是该领域的学术权威。通过分析关键词,我们确定了三个 IPF 研究热点群,分别是“临床研究”、“发病机制研究”和“诊断研究”。
我们通过文献计量分析评估了过去十年中所有关于 IPF 研究的出版物。目前该领域的研究热点是使用尼达尼布和吡非尼酮治疗该疾病的药物治疗。未来的研究将集中在开展多中心随机对照试验,以探索和评估新的 IPF 治疗药物。希望本研究能为进一步研究和新治疗药物的开发提供信息和数据支持。